Suppr超能文献

促纤维组织增生性小圆细胞肿瘤依赖于EWS-WT1转录因子。

Desmoplastic small round cell tumor is dependent on the EWS-WT1 transcription factor.

作者信息

Gedminas Jenna M, Chasse Maggie H, McBrairty Mitchell, Beddows Ian, Kitchen-Goosen Susan M, Grohar Patrick J

机构信息

Van Andel Research Institute, Grand Rapids, MI, USA.

Division of Pediatric Hematology/Oncology, Helen DeVos Children's Hospital, Grand Rapids, MI, USA.

出版信息

Oncogenesis. 2020 Apr 28;9(4):41. doi: 10.1038/s41389-020-0224-1.

Abstract

Desmoplastic small round cell tumor (DSRCT) is a rare and aggressive soft-tissue malignancy with a poor overall survival and no effective therapeutic options. The tumor is believed to be dependent on the continued activity of the oncogenic EWS-WT1 transcription factor. However, the dependence of the tumor on EWS-WT1 has not been well established. In addition, there are no studies exploring the downstream transcriptional program across multiple cell lines. In this study, we have developed a novel approach to selectively silence EWS-WT1 without impacting either wild-type EWSR1 or WT1. We show a clear dependence of the tumor on EWS-WT1 in two different cell lines, BER and JN-DSCRT-1. In addition, we identify and validate important downstream target pathways commonly dysregulated in other translocation-positive sarcomas, including PRC2, mTOR, and TGFB. Surprisingly, there is striking overlap between the EWS-WT1 and EWS-FLI1 gene signatures, despite the fact that the DNA-binding domain of the fusion proteins, WT1 and FLI1, is structurally unique and classified as different types of transcription factors. This study provides important insight into the biology of this disease relative to other translocation-positive sarcomas, and the basis for the therapeutic targeting of EWS-WT1 for this disease that has limited therapeutic options.

摘要

促纤维增生性小圆细胞肿瘤(DSRCT)是一种罕见的侵袭性软组织恶性肿瘤,总体生存率低且没有有效的治疗选择。该肿瘤被认为依赖致癌性EWS-WT1转录因子的持续活性。然而,肿瘤对EWS-WT1的依赖性尚未得到充分证实。此外,尚无研究探索多个细胞系中的下游转录程序。在本研究中,我们开发了一种新方法,可选择性沉默EWS-WT1,而不影响野生型EWSR1或WT1。我们在两种不同的细胞系BER和JN-DSCRT-1中显示出肿瘤对EWS-WT1有明显依赖性。此外,我们鉴定并验证了在其他易位阳性肉瘤中通常失调的重要下游靶标途径,包括PRC2、mTOR和TGFB。令人惊讶的是,尽管融合蛋白WT1和FLI1的DNA结合结构域在结构上是独特的且被归类为不同类型的转录因子,但EWS-WT1和EWS-FLI1基因特征之间存在显著重叠。本研究为该疾病相对于其他易位阳性肉瘤的生物学特性提供了重要见解,并为针对这种治疗选择有限的疾病进行EWS-WT1治疗靶向提供了依据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba86/7188842/9bf25a6ea44b/41389_2020_224_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验